Intratumoral Immunotherapy Strategies for Cancer Treatment

Intratumoral immunotherapy harnesses the patient’s own tumour as an in situ source of antigen by directly administering immune-modulating agents into lesions. This approach aims to reprogramme an immunosuppressive tumour microenvironment into one that supports antigen presentation, effector cell recruitment and systemic antitumour immunity. Strategies include the delivery of cytokines, toll-like receptor agonists, engineered nanoparticles, dendritic cell formulations and viral vectors directly into tumours. By concentrating immunostimulatory payloads at the disease site and minimising systemic exposure, intratumoral administration can enhance local retention, promote immunogenic cell death and trigger broader T-cell responses against distal metastases. Contemporary research seeks to optimise pharmacokinetics within the tumour matrix, identify combinations that synergise with checkpoint blockade or radiation, and develop materials that co-localise hyperthermia or adjuvancy to amplify therapeutic efficacy.

Research from Nature Portfolio

Recent studies have established a quantitative framework for the pharmacokinetics of locally administered cytokines. By modulating molecular size and affinity for extracellular matrix components, investigators demonstrated that extended tumour retention of interleukin-2 markedly improves disease control in preclinical models, informing rational design of protein-based immunotherapies. In parallel, a bacterial biomineralization-derived nanomaterial combining a gold core with surface-bound microbial components was shown to engage multiple pattern recognition receptors and, upon laser-induced hyperthermia, to enhance vascular perfusion, effector lymphocyte infiltration and cytokine release. This multifunctional construct selectively amplifies local immunity and potentiates the effects of established chemo- and immunotherapeutic regimens in murine tumour models.

Intratumoral Immunotherapy Strategies for Cancer Treatment publication trend

The graph below shows the total number of articles in intratumoral immunotherapy strategies for cancer treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Intratumoral administration: Direct injection of therapeutic agents into a tumour lesion to achieve high local concentration.

In situ vaccination: Strategy using the tumour itself as the antigen source by delivering immune stimulants directly into the lesion.

Immunogenic cell death: A form of tumour cell demise characterised by release of danger signals that promote antigen presentation and adaptive immunity.

Pattern recognition receptors: Innate immune sensors that detect conserved microbial or damage-associated molecular structures and initiate inflammatory responses.

Matrix-targeting affinity: The propensity of a molecule to bind extracellular matrix components, thereby prolonging its retention in the tumour microenvironment.

References

1. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Frontiers in Immunology (2018).
2. Immunotherapeutic effects of intratumoral nanoplexed poly I:C. Journal for ImmunoTherapy of Cancer (2019).
3. Maximizing response to intratumoral immunotherapy in mice by tuning local retention. Nature Communications (2022).
4. Biosynthesized gold nanoparticles that activate Toll-like receptors and elicit localized light-converting hyperthermia for pleiotropic tumor immunoregulation. Nature Communications (2023).
5. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. Journal of Translational Medicine (2015).